Structure-based design of novel, dipeptide ligands targeting the pp60(Src) SH2 domain

被引：8
|
作者：
Shahripour, A
Para, KS
Plummer, MS
Lunney, EA
Holland, DR
Rubin, JR
Humblet, C
Fergus, JH
Marks, JS
Saltiel, AR
Sawyer, TK
机构：
[1] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT BIOCHEM, ANN ARBOR, MI 48105 USA
[2] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1997年 / 7卷 / 09期
关键词：
D O I：
10.1016/S0960-894X(97)00190-X
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Based on the X-ray structures of the pp60(Src) (Src) SH2 domain complexed with two high affinity phosphopeptide ligands (Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu, and Ac-pTyr-Glu-(D) under bar-Hcy-NH2; Hcy = homocyclohexylalanine), we report herein the design and structure-activity relationships of a series of novel dipeptide ligands targeting the Src SH2 domain. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码：1107 / 1112
页数：6
相关论文
共 50 条
  • [31] Imidazole-based ligands of the Src SH2 protein
    Deprez, P
    Mandine, E
    Vermond, A
    Lesuisse, D
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (09) : 1287 - 1289
  • [32] BINDING IN-VITRO OF PHOSPHOTYROSINE-CONTAINING PROTEINS TO PP60(C-SRC) SH2 DOMAIN DOES NOT CORRELATE WITH CEF CELL-TRANSFORMATION
    BOEUF, H
    MURPHY, J
    BIBBINS, KB
    VARMUS, HE
    ONCOGENE, 1995, 10 (03) : 433 - 438
  • [33] A novel phosphotyrosine mimetic 4′-carboxymethyloxy-3′-phosphonophenylalanine (Cpp):: Exploitation in the design of nonpeptide inhibitors of pp60Src SH2 domain
    Kawahata, N
    Yang, MG
    Luke, GP
    Shakespeare, WC
    Sundaramoorthi, R
    Wang, YH
    Johnson, D
    Merry, T
    Violette, S
    Guan, W
    Bartlett, C
    Smith, J
    Hatada, M
    Lu, XD
    Dalgarno, DC
    Eyermann, CJ
    Bohacek, RS
    Sawyer, TK
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (17) : 2319 - 2323
  • [34] SH2 domain binding to phosphopeptide ligands: potential for drug targeting
    Kasembeli, Moses M.
    Xu, Xuejun
    Tweardy, David J.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 1010 - 1022
  • [35] Structure-based design of peptidomimetics ligands that bind to the Grb2-SH2 domain.
    Schoepfer, J
    Gay, B
    Caravatti, G
    Garcia-Echeverria, C
    Fretz, H
    Rahuel, J
    Furet, P
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U282 - U282
  • [36] Inhibitors to the Src SH2 domain: A lesson in structure-thermodynamic correlation in drug design
    Henriques, DA
    Ladbury, JE
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 390 (02) : 158 - 168
  • [37] Structure-based design of a novel, osteoclast-selective, nonpeptide Src SH2 inhibitor with in vivo anti-resorptive activity.
    Sawyer, T
    Shakespeare, W
    Yang, M
    Bohacek, R
    Cerasoli, F
    Stebbins, K
    Sundaramoorthi, R
    Vu, C
    Pradeepan, S
    Metcalf, C
    Haraldson, C
    Merry, T
    Dalgarno, D
    Hatada, M
    van Schravendijk, M
    Violette, S
    Smith, J
    Guan, W
    Bartlett, C
    Iuliucci, J
    Weigele, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S516 - S516
  • [38] Phosphotyrosyl peptides targeted to the SH2 domain are potent inhibitors of the kinase activity of pp60c-src
    Ramdas, L
    Wang, W
    Budde, RJA
    McMurray, JS
    PEPTIDES FOR THE NEW MILLENNIUM, 2000, : 563 - 565
  • [39] Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3
    Deng, Lin
    Mo, Jianshan
    Zhang, Yi
    Peng, Keren
    Li, Huaxuan
    Ouyang, Shumin
    Feng, Zongbo
    Fang, Wei
    Wei, Jianwei
    Rong, Deqin
    Zhang, Xiaolei
    Wang, Yuanxiang
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (19) : 13094 - 13111
  • [40] NMR STRUCTURAL STUDIES OF PP60(C-SRC) SH3-2 DOMAINS
    GAMPE, R
    XU, R
    DAVIS, D
    WORD, M
    RINK, M
    ELLIS, B
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 25 - 25
12345